PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).

Project Information

PAH-Advance

Grant agreement ID: 190143893

DOI 10.3030/190143893

Project closed

EC signature date 19 December 2022

Start date 1 January 2023

End date 31 December 2023

Funded under

• The European Innovation Council (EIC)

Total cost € 4 181 504,25

EU contribution € 2 500 000,00

Coordinated by

ATXA THERAPEUTICS LTD
Ireland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Conference proceedings (1)

A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects

Author(s): Kinsella BT, Reid HM, Mulvaney EP, Boyce M, Yamaoto T, Maginn M, Perkins C
Published in: American Journal of Respiratory and Critical Care Medicine, Issue 207, 2023, ISSN 1535-4970
Publisher: American Thoracic Society
DOI: 10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A3780

Peer reviewed articles (1)

Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial

Author(s): Reid HM, Maginn M, Perkins CM, Mulvaney EP, Boyce M, Yamamoto T, Kinsella BT
Published in: Frontiers in Pharacology, 2023, ISSN 1663-9812
Publisher: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1296188